

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 May 2023 (25.05.2023)



(10) International Publication Number
WO 2023/092112 A1

(51) International Patent Classification:

A61K 45/06 (2006.01) *A61K 31/713* (2006.01)
C12Q 1/68 (2006.01) *A61P 25/06* (2006.01)
C12N 15/00 (2006.01) *A61P 25/04* (2006.01)

(21) International Application Number:

PCT/US2022/080208

(22) International Filing Date:

21 November 2022 (21.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/281,640 20 November 2021 (20.11.2021) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **PRAVEEN, Kavita**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **COPPOLA, Giovanni**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BARAS, Aris**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **LEGAARD, Paul K.** et al.; Armstrong Teasdale LLP, 7700 Forsyth Boulevard, Suite 1800, St. Louis, Missouri 63105 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: METHODS OF TREATING HEADACHES AND MIGRAINES WITH SODIUM VOLTAGE-GATED CHANNEL ALPHA SUBUNIT 11 (SCN11A) INHIBITORS

(57) Abstract: The present disclosure provides methods of treating a subject having a headache or a migraine or preventing a subject from developing a headache or a migraine by administering an Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) inhibitor, and methods of identifying subjects having an increased risk of developing a headache or a migraine.

WO 2023/092112 A1